High response rates with new treatments for advanced ovarian cancer

Abstract

Response rates of up to 89% have been achieved in patients with advanced ovarian cancer who received novel antineoplastic therapy combinations. Antitumour activity has also been demonstrated by an immunotherapeutic vaccine, leading to the long-term stabilisation of disease in many patients. These promising new approaches to treating advanced ovarian cancer were described at the 6th International Congress on Anti-Cancer Treatment [ Paris, France; February 1996 ].